The Genetics Company is a privately held drug discovery and development company active in the areas of cancer and neurodegenerative diseases. The company has identified small molecule inhibitors of two proprietary targets with in the Wnt-pathway, which is believed to play a crucial role in colon cancer. It has also identified small molecule inhibitors of BACE (beta-amyloid converting enzyme). In parallel, the company has identified and is in the process of further characterizing a series of novel growth-related drug target candidate genes for exploitation in cancer therapy. Headquartered in Zurich-Schlieren, Switzerland, the company currently has 29 employees.\nThe Genetics Company offers you a range of high quality products to analyze Amyloid beta peptides x-40 and x-42 for basic research but also for pre-clinical and clinical development and in vitro diagnostics (IVD).\nIts CE-certified ELISA kits are the only clinically validated products for the determination of the Abeta42/40-Ratio in human CSF. These kits enable the early diagnosis of incipient Alzheimer's disease and can be used for patient stratification and monitoring in clinical trials of Alzheimer drug candidates.

Zhejiang Lanmei Technology Co., Ltd., established on 2010-10-25, Business scope includes agricultural technology,Food Science and Technology,mechanical engineering,Environmental Science and Technology Research,to develop,transfer;Agricultural product development;breeding,Research on Seedling Technology,to develop;food business(The specific business items are subject to the approval of the license or approval document);Production and operation:urban green seedlings,Economic seedlings,flowers(The above scope is operated with a valid license);Manufacturing and sales:Nutrient soil;to plant:fruit,nut;wholesale,retail:Edible produce;Engaged in the import and export of goods and technology(Except for the items in the negative list for foreign investment access in the above scope)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Brainwave Discovery is now increasingly focussed on using its high throughput drug screening technology to discover compounds that are potential treatments for Alzheimer's disease. BWD is based on science from the University of Edinburgh and University of Glasgow. BWD has been trading since 2010 as a contract research organisation and was identified by Scottish Enterprise as a company with significant growth potential.

Konkuk University Industry-Academic Cooperation Foundation increases the competitiveness of industries by linking company and university.